Non-coding RNA in drug resistance of hepatocellular carcinoma - PubMed (original) (raw)

Review

. 2018 Oct 9;38(5):BSR20180915.

doi: 10.1042/BSR20180915. Print 2018 Oct 31.

Affiliations

Review

Non-coding RNA in drug resistance of hepatocellular carcinoma

Bisha Ding et al. Biosci Rep. 2018.

Abstract

Hepatocellular carcinoma (HCC) has been one of the most highly lethal cancers. The acquisition of drug resistance accounts for the majority of poor effects of chemotherapy in HCC. Non-coding RNAs (ncRNAs) including miRNAs, long ncRNAs (lncRNAs), and circular RNA (circRNA) have been well-documented to participate in cancer occurrence and progression. Recently, multiple studies have highlighted the key roles of ncRNAs in chemoresistance of HCC. In addition, accumulating evidence has demonstrated that they can serve as biomarkers in diagnosis, treatment, and prognosis of HCC. In this review, we first overviewed up-to-date findings regarding miRNA and lncRNA in drug resistance of HCC, then summarized specific mechanisms that they modulate chemoresistance of HCC, and finally discussed their potential clinical application in overcoming the obstacle of HCC chemoresistance in the future.

Keywords: HCC; chemoresistance; drug resistance; hepatocellular carcinoma; long non-coding RNA; microRNA.

© 2018 The Author(s).

PubMed Disclaimer

Conflict of interest statement

The authors declare that there are no competing interests associated with the manuscript.

Figures

Figure 1

Figure 1. NcRNAs involved in drug resistance of HCC

HCC largely caused by chronic HBV infection, and the effect of chemotherapy was seriously limited by drug resistance. A lot of ncRNAs are involved in drug resistance of HCC. These ncRNAs can mediate the sensitivity of single-antitumor drug or multi-antitumor drug of HCC, and the molecular mechanisms constitute a complicated network machinery.

Similar articles

Cited by

References

    1. Torre L.A., Bray F., Siegel R.L., Ferlay J., Lortet-Tieulent J. and Jemal A. (2015) Global cancer statistics, 2012. CA Cancer J. Clin. 65, 87–108 10.3322/caac.21262 - DOI - PubMed
    1. Mazzoccoli G., Miele L., Oben J., Grieco A. and Vinciguerra M. (2016) Biology, epidemiology, clinical aspects of hepatocellular carcinoma and the role of sorafenib. Curr. Drug Targets 17, 783–799 10.2174/1389450117666151209120831 - DOI - PubMed
    1. Finn R.S., Zhu A.X., Farah W., Almasri J., Zaiem F., Prokop L.J. et al. (2018) Therapies for advanced stage hepatocellular carcinoma with macrovascular invasion or metastatic disease: a systematic review and meta-analysis. Hepatology 67, 422–435 10.1002/hep.29486 - DOI - PubMed
    1. Kanthaje S., Makol A. and Chakraborti A. (2018) Sorafenib response in hepatocellular carcinoma: microRNAs as tuning forks. Hepatol. Res. 48, 5–14 10.1111/hepr.12991 - DOI - PubMed
    1. Birney E., Stamatoyannopoulos J.A., Dutta A., Guigo R., Gingeras T.R., Margulies E.H. et al. (2007) Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature 447, 799–816 10.1038/nature05874 - DOI - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources